Metastatic liver cancer, i.e. secondary liver cancer, can often achieve a five-year survival rate ranging from 5% to 20% after treatment with surgery and other therapies, depending on the specific condition. Liver cancer is a common malignant tumor, which can be divided into primary liver cancer and secondary liver cancer, the latter being caused by other malignant tumors, such as gastric cancer, lung cancer, pancreatic cancer and so on, that have metastasized to the liver at an advanced stage. In this period, non-surgical therapies such as radiotherapy, chemotherapy and targeted therapy can be supplemented, and some tumors (e.g. gastric cancer, colon cancer) can be surgically resected according to the effect of neoadjuvant therapy. After active treatment, metastatic liver cancer patients can obtain a five-year survival rate of about 5% to 20%, but the purpose of treatment in this period is to prolong the survival period and improve the quality of life.